echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > ALS-4, a new drug for methicillin-resistant Staphylococcus aureus (MRSA) infection, is about to begin phase I clinicalization

    ALS-4, a new drug for methicillin-resistant Staphylococcus aureus (MRSA) infection, is about to begin phase I clinicalization

    • Last Update: 2021-01-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Biopharmaceutical company Aptorum recently announced that it has obtained permission from Health Canada to begin phase I research on ALS-4.
    ALS-4 is a new type of oral small molecule.
    ALS-4 may reduce antimicrobial resistance by reducing selection pressure and making bacteria susceptible to host immunity removal.
    the goal of ALS-4 is to treat methicillin-resistant Staphylococcus aureus (MRSA) infection, 1 alone or in combination with other existing antibiotics such as vancomycin.
    methicillin-resistant Staphylococcus aureus (MRSA) is a unique strain of Staphylococcus aureus that is resistant to almost all penicillin antibiotics, including methicillin and other penicillins that are resistant to β endamidease.
    first discovered in the UK in 1961 and is now widely known as a "superbug".
    Aptorum plans to conduct Phase I clinical trials in Canada, with the goal of recruiting 48 and 24 healthy volunteers to participate in single incremental dose (SAD) and multiple incremental dose (MAD) queues, respectively.
    the main purpose of the trial was to assess the safety and tolerance of oral ALS-4 to healthy subjects.
    secondary purpose is to evaluate the pharmacological dynamics characteristics of ALS-4.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.